Department of Oncological and Interventional Radiology, Businco Hospital, 09121 Cagliari, Italy.
Department of Radiology, Hospital del Mar, 08003 Barcelona, Spain.
Curr Oncol. 2023 Apr 19;30(4):4257-4268. doi: 10.3390/curroncol30040324.
(1) Background: Cement distribution after radiofrequency ablation of spinal metastases can be unpredictable due to various tumor factors, and vertebral augmentation requires advanced devices to prevent cement leakage and achieve satisfactory filling. The purpose of this study is to evaluate the safety and efficacy of a platform of steerable technologies with an articulating radiofrequency ablation (RFA) probe and targeted cavity creation before vertebral augmentation in the treatment of painful spinal metastases. (2) Methods: Sixteen patients (mean age, 67 years) underwent RFA in conjunction with vertebral augmentation after the creation of a targeted balloon cavity for metastatic spinal disease and were followed up to 6 months. Pain and functional mobility were assessed before treatment and postoperatively using the Visual Analogue Score (VAS) and Functional Mobility Scale (FMS). Complications, predictability of cement distribution, anatomical restoration, and local recurrence were collected. Technical success was defined as successful intraoperative ablation and predictable cement distribution after cavity creation without major complications. (3) Results: Sixteen patients with 21 lesions were treated for tumors involving the thoracolumbar spine. All treatments were technically successful and were followed by targeted cavity creation and vertebral augmentation. A statistically significant reduction in median VAS score was observed before treatment and 1 week after RFA treatment ( < 0.001). A total of six of the seven patients who reported limited painful ambulation before treatment reported normal ambulation 1 month after treatment, while the remaining patient reported no improvement. Patients who reported wheelchair use before treatment improved to normal ambulation (four/eight) or limited painful ambulation (four/eight). The improvement in mobility before and after treatment was statistically significant ( = 0.002). Technical success was achieved in all the combined procedures. (4) Conclusions: The combined treatment of RFA and vertebral augmentation with a steerable platform that allows the creation of a targeted cavity prior to cement injection proved to be a safe and effective procedure in our patient sample, resulting in improved quality of life as assessed by the Visual Analogue Score (VAS) and Functional Mobility Scale (FMS).
(1)背景:由于各种肿瘤因素,脊柱转移瘤射频消融后水泥分布可能不可预测,椎体增强需要先进的设备来防止水泥渗漏并达到满意的填充效果。本研究的目的是评估具有可转向技术平台的安全性和有效性,该平台具有可弯曲的射频消融(RFA)探头和靶向球囊创建技术,用于治疗疼痛性脊柱转移瘤。
(2)方法:16 例(平均年龄 67 岁)患者在转移性脊柱疾病靶向球囊造腔后接受 RFA 联合椎体增强治疗,并随访至 6 个月。采用视觉模拟评分(VAS)和功能移动量表(FMS)评估治疗前后的疼痛和功能移动能力。收集并发症、水泥分布的可预测性、解剖学恢复和局部复发情况。技术成功定义为术中消融成功和球囊造腔后可预测的水泥分布,无严重并发症。
(3)结果:16 例 21 个病灶患者的胸腰椎脊柱肿瘤接受治疗。所有治疗均技术成功,随后进行靶向球囊创建和椎体增强。治疗前和 RFA 治疗后 1 周的 VAS 评分中位数均有显著降低(<0.001)。治疗前报告活动受限性疼痛的 7 例患者中,有 6 例报告 1 个月后可正常活动,而其余 1 例患者报告无改善。治疗前报告轮椅使用的患者改善为正常活动(4/8)或活动受限性疼痛(4/8)。治疗前后活动能力的改善有统计学意义(=0.002)。所有联合手术均达到技术成功。
(4)结论:在我们的患者样本中,使用允许在水泥注射前创建靶向球囊的可转向平台进行 RFA 和椎体增强联合治疗是一种安全有效的方法,通过视觉模拟评分(VAS)和功能移动量表(FMS)评估,患者的生活质量得到改善。